Introduction
Chronic myeloid leukaemia (CML) is a clonal, myeloproliferative disease (1) . The annual incidence of CML is 1-2 cases per 100,000 individuals and the median age of presentation is 45-55 years, accounting for 15-20% of leukemia cases in adults (2) . Based on clinical character istics and laboratory findings, CML is often divided into three phases, chronic phase (CP), accelerated phase (AP) and blast phase (BP). Without intervention, CML typically begins in CP and over the course of several years progresses to AP, followed by BP. If administered early, drug treatment prevents this progression to a certain degree. A significant driver of progression from CP through AP and BP is the acquisition of additional chromosomal abnormalities to the Philadelphia (Ph) chromosome (2) .
As the first consistent chromosomal abnormality associated with a specific type of leukemia, the identification of the Ph chromosome in 1960 by Nowell and Hungerford was a breakthrough in cancer biology (3) . The Ph chromosome is the result of a t(9;22) reciprocal chromosomal translocation (4), involving the V-abl Abelson murine leukemia viral oncogene homolog 1 (ABL) proto-oncogene normally located on chromosome 9 and the breakpoint cluster region (BCR) gene on chromosome 22 (5) . The translocation results in deregulation of ABL tyrosine kinase activity and is defined as the pathogenetic principle (6) . In addition to the classic BCR-ABL translocation in CML (7) , a number of other gene fusions that contribute to oncogenesis have been reported in previous studies (8) . Gene fusions are the result of aberrant chromosomal translocations that join together the exons of two unrelated genes, producing a chimeric mRNA transcript and protein (9) . Previously, massively parallel RNA sequencing (RNA-Seq) was performed to identify gene fusions (10) . RNA-Seq enables identification of gene fusions in individual cancer samples and facilitates comprehensive understanding of cellular transcriptomes (11, 12) through profiling the entire transcriptome at a level of detail unattainable by microarray (13) .
In the present study, we performed RNA-Seq to detect gene fusions in a patient who did not present with common types of BCR-ABL gene fusions. Using an improved pipeline based on two tools for the detection of gene fusion, we identified several candidates of gene fusion in CP, including BCR-ABL1 and a novel gene fusion ring finger protein 213 (RNF213)-solute carrier family 26, member 11 (SLC26A11). Expression levels and functional domain change of the novel gene fusion were analyzed using a bioinformatic method and compared with genes involved in normal tissue funtion. 9 /l). In addition to increased myeloblast and progranulocyte levels, additional symptoms were identified, including blood dilution and splenomegaly demonstrated using ultrasonography. However, b3a2 b2a2 and ela2 fusion junctions in the BCR-ABL gene were not detected in 2008. One year later, detection of the classic BCR-ABL breakpoint remained negative.
Materials and methods

Sample information.
Written informed consent from the patient was obtained and the present study was reviewed and approved by the Clinical Laboratories Department of the People's Hospital in Jiang Yin City (Jiang Yin, China).
Library preparation. Total RNA was extracted from the peripheral blood using TRIzol according to the manufacturer's instructions (Invitrogen, Carlsbad, CA, USA). Following the TruSeq RNA SamplePrep Guide (Illumina, Inc., San Diego, CA, USA), the Illumina standard kit was used for mRNA-Seq sample preparation. Briefly, 10 µg of total RNA extracted from the sample was used for polyA mRNA selection with polyT oligo-conjugated magnetic beads by two rounds of purification, followed by thermal mRNA fragmentation. Using reverse transcriptase (SuperScript II) and random primers, the fragmented mRNA was subjected to cDNA synthesis. Following this, cDNA was converted into double-stranded cDNA and after end repair [Klenow fragment, T4 polynucleotide kinase, T4 polymerase and 3-' A' add process (Klenow exo-fragment)] the product was ligated to Illumina Truseq adaptors. A 2% agarose gel was used to perform size selection, which generated 380-bp cDNA libraries. Finally, the libraries were enriched through 15 cycles of PCR and purified with the QIAquick PCR purification kit (Qiagen, Hilden, Germany). Elution buffer was used to dilute the enriched libraries to a final concentration of 10 nM.
Primary analysis. Libraries from CML blood in CP were analyzed at a concentration of 11 pM on a single Genome Analyzer IIx (GAIIx) lane using 115-bp sequencing. Raw RNA-Seq data were filtered using FASTx-tools (http:// hannonlab.cshl.edu/fastx_toolkit/) according to the following criteria: i) reads containing sequencing adaptors were removed; ii) nucleotides with a quality score <20 were trimmed from the end of the sequence; iii) reads <50 were discarded; and iv) artificial reads were removed. Following the filtering pipeline, all clean reads were trimmed to 90 bp long due to 3' low quality base. A total of 3.2 Gbp (3, 193, 208, 820) of cleaned, paired-end reads was produced. Raw sequence data were submitted to the NCBI Short Read Archive (accession number, SRP011486).
Reads mapping and expression estimation. Clean and trimmed reads were aligned with the Ensembl H. sapiens reference genome (build GRCh37) using TopHat v1.3.3 (14) . The program initially removes a portion of the reads based on quality information accompanying each read and then aligns the reads to the reference genome. TopHat allows multiple alignments per read (up to 20 by default) and a maximum of two mismatches when mapping the reads to the reference genome. The default parameters were used. Aligned read files were then processed by Cufflinks v1.2.1 (15) , which measures the relative expression of the genes with the normalized RNA-Seq fragment counts. Fragments per kilobase of exon per million fragments mapped (FPKM) is used as the unit of measurement. A Bayesian inference method (16) was used to calculate confidence intervals for FPKM estimates. The reference GTF annotation file used in Cufflinks was downloaded from the Ensembl database (Homo_sapiens.GRCh37.63. gtf) (17) . The gene expression data were submitted to the GEO database (accession ID, GSE36522).
Gene fusion prediction. Using TopHat, all filtered RNA-Seq reads were mapped to the reference transcriptome, which was downloaded from the Ensembl database (Homo_sapiens. GRCh37.63.cdna.all.fa). Read pairs mapping to the same transcripts were removed. Remaining reads were analyzed by two software packages, deFuse (deFuse-0.4.2) (18) and TopHat-Fusion (TopHat-Fusion-0.1.0) (19) , to identify candidate gene fusions. The bowtie-index used in the TopHat-Fusion was downloaded from the TopHat homepage (H. sapiens UCSC hg19). The parameters of the TopHat-Fusion used were obtained from the 'Getting Started' (http://tophat-fusion. sourceforge.net/tutorial.html) tutorial. The deFuse parameters used were default.
Candidate gene fusion filtering. deFuse results were filtered according to McPherson et al (18) and Steidl et al (20) . Two candidate gene fusions were obtained following the filtering pipeline. The TopHat-Fusion results were parsed by in-house Perl scripts and filtered according to the following pipeline: i) span reads were >8 reads; ii) ratio of against reads vs. span reads was <0.5; and iii) gene fusions involving ribosomal proteins or small nuclear ribosomal proteins were excluded. Following parsing, only one filtered candidate fusion remained. Filtered candidates detected simultaneously by deFuse and TopHat-Fusion were considered reliable candidate gene fusions. Following this filtering pipeline, a single reliable candidate, RNF213-SLC26A11, was obtained.
Improvement of filtering method.
To reduce the false-positive rate and remove read-throughs, we improved the filtering standard by comparing the conditions of our filtering method with those of the final results. Two filtering standards of deFuse were modified: i) the number of splitr_count was revised according to the average coverage of the sequencing depth and ii) the events, which happened between 2 adjacent genes without any eversion or inversion, were considered to be produced by read-through. The detailed conditions of the 14 candidates are listed in Table I .
Gene fusion validation.
To detect fusion transcripts, we designed a forward primer targeting the 5' partner gene and reverse primer targeting the 3' partner. Primer pairs (Table II) for the coding exons of the fusion genes were generated using Primer 5 software (Premier Biosoft International, Palo Alto, CA, USA) and the PCR volume comprised 20 µl sample, 2 µl 10X PCR buffer, 2 µl cDNA template, 0.4 µl dNTP, 0.4 µl Taq enzyme (Genscript, Piscataway, NJ, USA) and 0.2 pmol/µl each oligonucleotide. PCR was performed using the following procedure: 95˚C for 2 min, 35 cycles of 95˚C for 15 sec, 62˚C for 20 sec and 72˚C for 20 sec, followed by 72˚C for 2 min. The presence of the fusion gene in the CML blood sample was confirmed. PCR products of the fusion gene were cloned in the pGEM ® -T Easy Vector (Promega Corp., Madison, WI, USA) and then sequenced with the T7 primer using an Applied Biosystems 3730 DNA Analyzer (Life Technologies Corporation, USA).
Gene fusion visualization. Views of the candidate gene fusions were generated by running CIRCOS (available at http://circos. ca/). Reads coverage of the candidate gene fusions in the sample were observed in the Integrative Genomics Viewer (IGV).
Results
Characterization of sequencing and mapping. CML blood in CP was obtained from a male patient of 78 years old. The peripheral blood smear is demonstrated in Fig. 1 . Massively parallel paired end cDNA sequencing was performed using the Illumina Genome Analyzer IIx. In total, 43.6 million raw reads were produced. Following filtering and trimming, 35.5 million clean reads were obtained. All reads were aligned to the reference genome by TopHat. In summary, 15.3 million read pairs were uniquely aligned. Reads (74%) were mapped to Ensembl reference genes. The average Table I . (Table I) . Among the candidates, one gene fusion event RNF213-SLC26A11 was detected by deFuse and TopHatFusion with a 3-bp breakpoint shift.
Improvement of filtering gene fusion.
The majority of candidate gene fusions were identified within the same chromosome (Table I) . Using manual checks and selection, we identified that the majority of fusion events occurred between adjacent genes on the same chromosome, which were usually regarded as read-through (21), while only two candidates, including RNF213-SLC26A11 and BCR-ABL1, were the most reliable gene fusion pairs. BCR-ABL is a well-documented gene fusion in CML and is used as a standard method for CML diagnosis (22) . The RNF213-SLC26A11 fusion has not been previously identified in CML. In the present study, this novel fusion was further validated by reverse trans cription polymerase chain reaction (RT-PCR) and the function of 
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RNF213-SLC26A11 was predicted using bioinformatic methods.
RT-PCR validation of RNF213-SLC26A11.
To experimentally confirm the novel gene fusion identified by RNA-Seq, the expression level of RNF213-SLC26A11 in the sample was validated by RT-PCR. A primer pair, located at the second intron of RNF213 (5'-GACTCCTGCTCTTGCTTC TGG-3') and the 8th exon region of SLC26A11 (5'-ATCGTC CCGTTGGCTGTG-3') was designed. The results confirmed the existence of the fusion event in the sample (Fig. 2C) , consistent with conclusions based on RNA-Seq analysis.
Identification of novel gene fusion RNF213-SLC26A11.
As demonstrated in Fig. 2A , RNF213 and SLC26A11 are adjacent gene pairs located in chromosome 17 separated by 7 kbp. The genes are transcribed in the same direction in wild-type individuals. In the present sample, we observed a fusion between the second intron of RNF213 and the eighth exon of SLC26A11, generating a chimeric RNF213-SLC26A11 transcript, which has not previously been identified.
Analysis of reads coverage for RNF213 and SLC26A11.
Analysis of reads coverage of RNF213 and SLC26A11 demonstrated that each exon of RNF213 was expressed at normal levels and the first 7 exons of SLC26A11 were expressed at extremely low levels (Fig. 2B) , indicating that i) the RNF213-SLC26A11 fusion may occur in the majority of cells or ii) the fusion event altered expression of SLC26A11 using the promoter of RNF213, largely caused by the duplication of the first 2 exons of RNF213. RNF213 was normally expressed.
In addition, compared with domains of the whole SLC26A11 gene under normal conditions (Fig. 3A) , specific domains of the gene SLC26A11 in the chimeric transcript, including Sulfate_tra_GLY (pfam13792), EF_0839 (TIGR03581), sulfate_transp (pfam00916), sulP (TIGR00815), SUL1 (COG0659) and PRK11660 (PRK11660), were partially damaged (Fig. 3B ). These observations indicate that the normal function of RNF213 did not appear to be affected, while loss of function in SLC26A11 was identified. However, further investi gation is required to understand the specific mechanism and functional consequence of this fusion event. Identification of recurrent gene fusion. In addition to the novel gene fusion, we identified another gene fusion candidate, which had been previously identified in CML (23) . As demonstrated in Fig. 4B , BCR is located in chromosome 22 while ABL1 is on chromosome 9. In the present sample, a fusion was identified between the first intron of BCR and the second exon of ABL1, generating a chimeric transcript BCR-ABL1 (Fig. 4) . Deininger et al (24) previously reported that this fusion is a e1a2 fusion junction and is extremely rare (25) .
Discussion
A number of methods are currently available for the detection of gene fusions, including chromosome banding analysis (karyotyping) followed by fluorescence in situ hybridization studies and molecular analysis based on RT-PCR (26) . The RNA-Seq method currently enables genome-wide identification of novel fusion transcripts at the highest resolution level (8, 27, 28) . The BCR-ABL fusion transcript is considered to be a major consequence of the Ph translocation in CML (29) .
In the present study, whole transcriptome high-throughput sequencing was performed to detect additional fusion events to BCR-ABL, consistent with clinical diagnosis of CML.
Using an improved bioinformatics method and RT-PCR, we identified extremely low levels of BCR-ABL1 in an ela2-type sample (FPKM: BCR=20.28, ABL=9.80). An additional novel gene fusion was also discovered.
To obtain the most reliable gene fusion candidates in the blood sample obtained from a CML patient in CP, the filtering method of deFuse was improved. Sample analysis using deFuse and TopHat-Fusion methods identified several gene fusion candidates. TopHat-Fusion results were filtered, mapping reads were checked manually and ribosomes were removed from the raw results produced by deFuse to obtain 14 gene fusion candidates. However, the majority of candidates were identified within the chromosome. Following detailed observation in IGV and improvement of the filtering method of deFuse, two reliable gene fusions were identified, including the novel gene fusion RNF213-SLC26A11 and the recurrent gene fusion BCR-ABL1.
From analysis of the structure of the novel chimeric transcript RNF213-SLC26A11, we identified that SLC26A11 expression is largely mediated by promoter displacement of RNF213. SLC26A11 was initially characterized as a putative sulfate transporter predominately expressed in high endothelial venules. SLC26A11 is widely expressed and mRNA expression has been identified in the kidney, placenta and brain (30) . The blood sample analyzed in the present study was obtained from a CML patient in CP. Expression of the first 7 exons of SLC26A11 in this sample was observed at extremely low levels (Fig. 2B) . In addition, SLC26A11 has been demonstrated to be expressed in the normal blood tissue in acute myoleid leukemia (http://www.genecards.org/ cgi-bin/carddisp.pl?gene=SLC26A11; http://www.genecards. org/info.shtml#expression_images). Furthermore, a number of domains identified in normal human samples of SLC26A11 were also identified to be damaged by the formation of the novel chimeric transcript RNF213-SLC26A11 (Fig. 3B) , including Sulfate_tra_GLY, EF_0839, sulfate_transp, sulP, SUL1 and PRK11660. STAS_SulP_like_sulfate_transporter (cd07042) and STAS (pfam01740) were observed to be unaffected. The present results indicate that the sulfate transport function of SLC26A11 was weakened, while its function in transport activity regulation and general NTP binding were maintained following fusion.
To explore the correlation between the RNF213-SLC26A11 gene fusion and CML, the invidual functions of RNF213 and SLC26A11 under normal conditions were identified. RNF213 encodes a protein containing a C3HC4-type RING finger domain, a specialized type of Zn-finger that binds two atoms of zinc and is thought to be involved in mediating proteinprotein interactions. The protein also contains an AAA domain, which is associated with ATPase activity. RNF213 is a susceptibility gene for Moyamoya disease, a vascular disorder of intracranial arteries (31) . In addition, the protein functions as a translocation partner in anaplastic large cell lymphoma and inflammatory myofibroblastic tumor cases. A t(2;17) (p23;q25) translocation has been identified with the anaplastic lymphoma kinase gene located on chromosome 2 and a t(8;17) (q24;q25) translocation has been identified with the MYC gene on chromosome 8 (31) . SLC26A11 encodes a member of the solute linked carrier 26 family of anion exchangers. Members of this family of proteins are essential for a number of cellular functions, including homeostasis and intracellular electrolyte balance. The encoded protein is a sodium-independent sulfate transporter that is sensitive to the anion exchanger inhibitor 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid (RefSeq, Oct 2009). These functions indicate that the novel gene fusion candidate RNF213-SLC26A11 commonly occurs and affects homeostasis to a limited degree only. At present, the impact of this fusion on CML remains unclear. The mechanism of this functional change and its affect on the blood during CML require further investigations.
In addition to identification of the novel gene fusion RNF213-SLC26A11, we identified the recurrent gene fusion BCR-ABL1 at extremely low levels of expression. Analysis of the structure of this gene fusion demonstrated that the transcript discovered in our sample exhibits a e1a2 fusion junction, producing a 190-kDa protein (P190BCR-ABL). P190BCR-ABL CML has been previously identified in only 1% of CML patients and this junction is correlated with poor response to therapy with tyrosine kinase inhibitors (TKIs), with few, usually short-lived responses. Individuals with this gene fusion must be identified as high-risk patients, monitored closely for efficacy during therapy with TKI and offered stem cell transplantation early if eligible for this procedure (25) .
Following improvement of the filtering method, we analyzed RNA-Seq data and discovered two gene fusions in a blood sample obtained from a CML patient in CP, including a novel gene fusion RNF213-SLC26A11 and the recurrent BCR-ABL1 fusion. In addition, the present study has demonstrated that the current filtering method of deFuse must be revised according to the average coverage of the sequencing depth. This is likely to enable the improved filtering method to be applied to gene fusion detection in other tumor tissues.
